{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T06:43:33Z","timestamp":1788072213739,"version":"build-2784847793"},"reference-count":36,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,2,7]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe the post-marketing safety profile of respiratory syncytial virus prefusion F (RSVpreF) vaccine among pregnant individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This study analysed adverse event (AE) reports submitted to the U.S. Food and Drug Administration\u2019s Vaccine Adverse Event Reporting System (VAERS) database following RSVpreF immunisation from 1 September 2023 to 23 February 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>VAERS, as a national spontaneous vaccine safety surveillance system, provides insights into the safety profile of the RSVpreF vaccine in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Surveillance data included all AE reports submitted to VAERS in pregnant individuals following vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Receipt of RSVpreF vaccine among pregnant individuals in the USA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Descriptive statistics were used to assess all AE reports with RSVpreF, including frequency, gestational age at vaccination, time to AE onset, reported outcomes and proportion of serious reports. Data mining techniques were employed to identify disproportionate reporting of RSVpreF-event pairs. Reports of preterm births were clinically reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>VAERS received 77 reports pertaining to RSVpreF vaccination in pregnant individuals, with 42 (54.55%) classified as serious. The most frequently reported non-pregnancy-specific AEs were headache, injection site erythema and injection site pain. For pregnancy-specific AEs, preterm birth was the most frequently reported (12.8%), followed by AE terms such as preterm premature rupture of membranes and caesarean section (each at 3.3%), and cervical dilatation, haemorrhage during pregnancy and uterine contractions during pregnancy (each at 1.4%). Our disproportionality analysis indicated signals for various AEs, particularly preterm birth, indicating that reports of preterm birth in conjunction with RSVpreF vaccination were observed more frequently than statistically expected. Most of the reported preterm births were moderate to late, occurring between 32 and less than 37 weeks of gestation. The median time from immunisation to the onset of preterm birth was 3 days, with two-thirds of cases reported within a week of vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The AEs reported to VAERS among pregnant individuals vaccinated with RSVpreF largely aligned with the safety profile observed in prelicensure studies; however, this analysis also highlights the previously observed safety signal for preterm birth. Active surveillance studies focusing on maternal and perinatal outcomes are needed to further evaluate this signal and guide future clinical recommendations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-087850","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T10:05:25Z","timestamp":1743847525000},"page":"e087850","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: a real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7500-0644","authenticated-orcid":false,"given":"Abdallah","family":"Alami","sequence":"first","affiliation":[{"name":"School of Epidemiology and Public Health, University of Ottawa, Faculty of Medicine, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9069-6512","authenticated-orcid":false,"given":"Santiago","family":"P\u00e9rez-Lloret","sequence":"additional","affiliation":[{"name":"Instituto Universitario de Ciencias de la Salud, Fundaci\u00f3n H.A Barcel\u00f3, Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas, Buenos Aires, Buenos Aires, Argentina"},{"name":"Department of Physiology, Faculty of Medicine, University of Buenos Aires, Buenos Aires, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5623-0874","authenticated-orcid":false,"given":"Donald R","family":"Mattison","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health, University of Ottawa, Faculty of Medicine, Ottawa, Ontario, Canada"},{"name":"Risk Sciences International, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"2025121511171694000_15.4.e087850.1","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.vaccine.2023.05.047","article-title":"Vaccine hesitancy in pregnant Women: A narrative review","volume":"41","author":"Mitchell","year":"2023","journal-title":"Vaccine (Auckl)"},{"key":"2025121511171694000_15.4.e087850.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0095-5108(18)30194-5"},{"key":"2025121511171694000_15.4.e087850.3","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy056"},{"key":"2025121511171694000_15.4.e087850.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00478-0"},{"key":"2025121511171694000_15.4.e087850.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2401072"},{"key":"2025121511171694000_15.4.e087850.6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.28950","article-title":"Infants Admitted to US Intensive Care Units for RSV Infection During the 2022 Seasonal Peak","volume":"6","author":"Halasa","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025121511171694000_15.4.e087850.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309189"},{"key":"2025121511171694000_15.4.e087850.8","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7241e1"},{"key":"2025121511171694000_15.4.e087850.9","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1136\/bmj.p2620","article-title":"Concerns over informed consent for pregnant women in Pfizer\u2019s RSV vaccine trial","volume":"383","author":"Boytchev","year":"2023","journal-title":"BMJ"},{"key":"2025121511171694000_15.4.e087850.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305478"},{"key":"2025121511171694000_15.4.e087850.11","unstructured":"Lawn J . Born too soon: the global action report on preterm birth. 2012."},{"key":"2025121511171694000_15.4.e087850.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106062"},{"key":"2025121511171694000_15.4.e087850.13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2216480"},{"key":"2025121511171694000_15.4.e087850.14","unstructured":"LABEL: abrysvo- respiratory syncytial virus vaccine kit. 2023. Available: https:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=be18292e-b1a2-4815-a0ed-003efaa6bea3"},{"key":"2025121511171694000_15.4.e087850.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p1021"},{"key":"2025121511171694000_15.4.e087850.16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0264-410X(94)90315-8","article-title":"The vaccine adverse event reporting system (VAERS)","volume":"12","author":"Chen","year":"1994","journal-title":"Vaccine (Auckl)"},{"key":"2025121511171694000_15.4.e087850.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"2025121511171694000_15.4.e087850.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2013.08.033"},{"key":"2025121511171694000_15.4.e087850.19","unstructured":"Pfizer Medical Information . ABRYSVO Adverse Reactions. 2025 Available: https:\/\/www.pfizermedicalinformation.com\/abrysvo\/adverse-reactions"},{"key":"2025121511171694000_15.4.e087850.20","unstructured":"Kochhar S . AESI case definition companion guide: preterm birth and assessment of gestational age. 2022."},{"key":"2025121511171694000_15.4.e087850.21","doi-asserted-by":"publisher","DOI":"10.1177\/0962280211403604"},{"key":"2025121511171694000_15.4.e087850.22","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742"},{"key":"2025121511171694000_15.4.e087850.23","unstructured":"Bate A . The use of bayesian confidence propagation neural network in pharmacovigilance: ume\u00e5 university. 2003."},{"key":"2025121511171694000_15.4.e087850.24","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0482-1"},{"key":"2025121511171694000_15.4.e087850.25","unstructured":"Centers for Disease Control and Prevention . Guidelines for Vaccinating Pregnant Women,"},{"key":"2025121511171694000_15.4.e087850.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-023-03482-8"},{"key":"2025121511171694000_15.4.e087850.27","unstructured":"Ahmed I , Poncet A . PhViD: an R package for pharmacovigilance signal detection. 2016."},{"key":"2025121511171694000_15.4.e087850.28","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1056\/NEJMoa2104983","article-title":"Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons","volume":"384","author":"Shimabukuro","year":"2021","journal-title":"N Engl J Med"},{"key":"2025121511171694000_15.4.e087850.29","unstructured":"U.S. Food and Drug Administration (FDA) . FDA approves first vaccine for pregnant individuals to prevent rsv in infants. 2023."},{"key":"2025121511171694000_15.4.e087850.30","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1016\/j.vaccine.2016.03.045","article-title":"Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data","volume":"34","author":"Quinn","year":"2016","journal-title":"Vaccine (Auckl)"},{"key":"2025121511171694000_15.4.e087850.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2011.06.047"},{"key":"2025121511171694000_15.4.e087850.32","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/AOG.0000000000004889","article-title":"Safety of Booster Doses of Coronavirus Disease 2019 (COVID-19) Vaccine in Pregnancy in the Vaccine Adverse Event Reporting System","volume":"140","author":"Moro","year":"2022","journal-title":"Obstetrics & Gynecology"},{"key":"2025121511171694000_15.4.e087850.33","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2004.039438"},{"key":"2025121511171694000_15.4.e087850.34","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/148616","article-title":"The problem of confounding in studies of the effect of maternal drug use on pregnancy outcome","volume":"2012","author":"K\u00e4ll\u00e9n","year":"2012","journal-title":"Obstet Gynecol Int"},{"key":"2025121511171694000_15.4.e087850.35","first-page":"10","article-title":"The complicated task of monitoring vaccine safety","volume":"112","author":"Ellenberg","year":"1997","journal-title":"Public Health Rep"},{"key":"2025121511171694000_15.4.e087850.36","first-page":"19","article-title":"Under-Reporting of Adverse Events Following Immunization Observed in a Single Hospital Setting in Italy","volume":"11","author":"Patrignani","year":"2019","journal-title":"Italian Journal of Pharmacoeconomics and Pharmacoutilization"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-087850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:17:25Z","timestamp":1765826245000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-087850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,5]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bmjopen-2024-087850"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-087850","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.04.19.24306090","asserted-by":"object"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}